Takeda and Harrington Discovery Institute at University Hospitals announce collaboration to advance the development of rare disease therapeutics

Thursday, April 27, 2017
Osaka, Japan and Cleveland, Ohio, USA – Takeda Pharmaceutical Company Limited (TSE: 4502), and Harrington Discovery Institute at University Hospitals in Cleveland, Ohio have announced a multi-year collaboration to accelerate breakthrough therapeutic discoveries in rare diseases.
 
A first of a kind partnership for Harrington Discovery Institute with a major pharmaceutical company, this collaboration with Takeda will build on Harrington Discovery Institute’s established operating model to create a new program specifically for the advancement of medicines for rare diseases. At the same time, this collaboration will complement Takeda’s strategic R&D focus in its therapeutic areas of oncology, gastroenterology and central nervous system disorders. The Harrington program will focus on M.D. and Ph.D. researchers from across the United States, developing disruptive and transformative research, which shows promise for translation into novel treatments.
 
“Takeda is committed to supporting and developing transformative therapies for social benefit – so are we,” said Jonathan S. Stamler, MD, President, Harrington Discovery Institute and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at University Hospitals and Case Western Reserve University School of Medicine. “We are delighted to see Takeda’s confidence in us to advance early stage discoveries in a major area of unmet medical need. Through this partnering model that bridges academia and industry, we will jointly leverage our financial and human capital to accelerate the pace of cures for rare diseases.”

Download full release


<< Back

You must be logged in to view this item.



Login

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.